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Background: This study examined the hemodynamic effects of Procyrion’s
catheter-deployed, partial circulatory support device in a porcine acute heart
failure (HF) model. Long-term circulatory support (LTCS) is currently limited to
large devices with invasive and risky surgical implantations and therefore is
restricted to NYHA Class IV HF patients. In contrast, Procyrion’s device is an
intra-aortic micro-axial entrainment pump implanted with cath-lab techniques and
is intended for LTCS in earlier stage HF patients.
Methods: The pump was deployed in the thoracic aorta and anchored using self-
expanding struts. Acute cardiac dysfunction was induced via continuous esmolol infusion
until cardiac contractility was 50% of the pre-esmolol baseline. Hemodynamic effects
were recorded using a pressure-volume catheter (left ventricle), a flow probe (renal artery)
and pressure catheters (aorta and renal artery). Effects were evaluated from changes in
hemodynamic parameters between baseline (device off) and device on.
Results: The intra-aortic pump increased cardiac output, stroke volume, ejection fraction,
and renal flow and pressure while decreasing cardiac stroke work, afterload and
end-diastolic pressure.
Conclusions: This study demonstrates that the catheter based intra-aortic fluid entrain-
ment pump improves porcine acute HF hemodynamics. Additionally, improved renal
perfusion may enhance HF treatment and disrupt cardiorenal syndrome. These results
suggest the intra-aortic pump has the potential to improve HF outcomes and quality-of-life
by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion.
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Background: Left ventricle (LV) remodeling after anterior wall myocardial infarction
(AWMI) leads to increased LV volumes, myocardial stress, and ultimately heart failure
(HF). Treatment options are limited for these high-risk HF patients. Two prior first-in-man
studies of PVR using the Parachute TM device support the safety and efficacy of this
approach. An ongoing study (Cohort B) was designed to confirm these observations and
to evaluate an extended range of 8 device sizes, prior to launching a U.S. pivotal
randomized controlled trial.
Methods: Aims: To confirm the acute safety and acute and long-term efficacy of PVR
using an expanded range of Parachute TM device sizes in patients with ischemic HF with
prior AWMI. Methods: Up to 60 patients with NYHA class II-IV HF secondary to
AWMI, with akinetic or dyskinetic wall motion abnormality, LV ejection fraction 40%,
and have been fully revascularized are being enrolled into this non-randomized trial at 15
European sites. Major endpoints were death and repeat hospitalization.
Results: As of June 1, 2012, 38 patients were treated. Parachute was implanted
successfully in all patients. There were no procedural (n38) or 30-day (n34) stroke or
death observed. Enrollment and 6 month FU on 30 patients will be completed by October
1, 2012. Results will be available for presentation.
Conclusions: This ongoing trial of PVR using an expanded range of Parachute TM
device sizes in patients with ischemic HF and prior AWMI is anticipated to confirm the
safety and efficacy of this approach to treating HF, thus supporting the conduct of a
subsequent RCT.
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Background: Medically refractory right ventricular failure (MR-RVF) is associated with
high in-hospital mortality and is managed with intra-aortic balloon counterpulsation, right
ventricular assist devices, atrial septostomy, or extracorporeal membrane oxygenation.
Limited data exist supporting use of the TandemHeart right ventricular support device
(TH-RVSD;CardiacAssist Inc) for MR-RVF.The goal of this study was to explore the
clinical utility of the TH-RVSD in MR-RVF.
Methods: We explored the clinical efficacy and safety of the TH-RVSD in 46 patients
with MR-RVF. All patient data was retrospectively collected in the TandemHeart RIght
VEntricular support (THRIVE) registry comprising 8 tertiary care hospitals in the United
States.
Results: MR-RVF was due to chronic heart failure in 7%(n3), myocarditis in
7%(n3), post-valve surgery in 32%(n15), post-orthotopic heart transplant in
11%(n5), post-left ventricular assist device surgery in 11%(n5), post-coronary bypass
grafting in 7%(n3), and acute myocardial infarction (AMI) in 26%(n12) of subjects.
Concomitant placement of a left ventricular assist device due to biventricular failure
occurred in 24%(n11) of subjects. Percutaneous(48%;n22) and surgical(52%;n24)
cannulation approaches were studied. No intra-procedural mortality was observed. Two
vascular complications were noted. Thrombolysis in Myocardial Infarction (TIMI) major
bleeding occurred in 42% of patients. Time from admission to TH-RVSD implantation
was 5.7	8.5 days with an average of 6769 789 rotations per minute, providing 4.2	1.3
L/min of flow. Mean duration of TH-RVSD use was 5.4	5.1 days. Compared to
pre-procedural values, mean arterial pressure (67	12vs74	14,p0.05), right atrial
pressure (21	9vs16	6,p0.05), pulmonary artery systolic pressure
(43	15vs33	15,p0.01), cardiac index (1.7	0.7vs2.5	1.1,p0.05), and mixed ve-
nous oxygen saturation (52	15vs.65	10,p0.01) improved within 48 hours of TH-
RVSD implantation. Total in-hospital mortality was 52.5%(n21) and was lowest
amongst acute IWMI patients (33%;n3).
Conclusions: Use of the TH-RVSD for MR-RVF is feasible and associated with
improved hemodynamics. Algorithms promoting mechanical RVSD use in MR-RVF
warrant further investigation.
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Background: A non-blood contacting, non-obligatory extra-ascending aortic counter-
pulsation Cuff and sense lead coupled to a percutaneous pneumatic drive system (C-Pulse;
Sunshine Heart, Inc, Eden Prairie MN) has been used in investigational clinical studies in
patients with moderate to severe heart failure. A fully implanted electrohydraulic
counterpulsation system utilizing the same Cuff design and incorporating both transcuta-
neous energy transfer (TET) and a defibrillator has been developed.
Methods: Following engineering analysis and cadaver fit studies, two electro-
hydraulic pumps were constructed; single liquid and dual liquid designs, both
using the same motor mechanism. The pump sits in the right pleural space and is
coupled to an extra-aortic inflatable Cuff via a short, wide lumen. The internal
controller has an attached internal TET coil, and also receives an IS-1 cable from
an implantable CRT-D pulse generator. The CRT-D and internal controller can be
programmed remotely. Integrated system testing was completed on the bench and
verified in an acute preclinical study.
Results: Bench testing demonstrated the systems provided 1:1 counterpulsation at
nominal physiological conditions (HR 80 bpm, MAP 90 mmHg, Cuff displace-
ment 14 cc per beat). These results correlated with preclinical testing in a calf
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